DB:6OP

Stock Analysis Report

Executive Summary

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases.


Snowflake Analysis

Excellent balance sheet with high growth potential.

Share Price & News

How has OSE Immunotherapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6OP has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-13.0%

6OP

-11.1%

DE Biotechs

-9.1%

DE Market


1 Year Return

-16.0%

6OP

-2.9%

DE Biotechs

2.9%

DE Market

Return vs Industry: 6OP underperformed the German Biotechs industry which returned -2.9% over the past year.

Return vs Market: 6OP underperformed the German Market which returned 2.9% over the past year.


Shareholder returns

6OPIndustryMarket
7 Day-13.0%-11.1%-9.1%
30 Day-14.8%-12.8%-7.2%
90 Day-5.0%-9.6%-6.5%
1 Year-16.0%-16.0%-2.7%-2.9%6.1%2.9%
3 Year-44.0%-44.0%25.8%24.4%3.5%-5.6%
5 Yearn/a1.6%-0.5%8.0%-6.8%

Price Volatility Vs. Market

How volatile is OSE Immunotherapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is OSE Immunotherapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 6OP (€3.67) is trading below our estimate of fair value (€426.62)

Significantly Below Fair Value: 6OP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 6OP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 6OP is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6OP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6OP is good value based on its PB Ratio (0.9x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is OSE Immunotherapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

47.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6OP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: 6OP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 6OP's is expected to become profitable in the next 3 years.

Revenue vs Market: 6OP's revenue (28.8% per year) is forecast to grow faster than the German market (5.1% per year).

High Growth Revenue: 6OP's revenue (28.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 6OP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has OSE Immunotherapeutics performed over the past 5 years?

3.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6OP is currently unprofitable.

Growing Profit Margin: 6OP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6OP is unprofitable, but has reduced losses over the past 5 years at a rate of 3.8% per year.

Accelerating Growth: Unable to compare 6OP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6OP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 6OP has a negative Return on Equity (-4.58%), as it is currently unprofitable.


Next Steps

Financial Health

How is OSE Immunotherapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 6OP's short term assets (€39.1M) exceed its short term liabilities (€20.7M).

Long Term Liabilities: 6OP's short term assets (€39.1M) exceed its long term liabilities (€11.5M).


Debt to Equity History and Analysis

Debt Level: 6OP's debt to equity ratio (8.2%) is considered satisfactory.

Reducing Debt: 6OP's debt to equity ratio has reduced from 80.1% to 8.2% over the past 5 years.


Balance Sheet

Inventory Level: 6OP has a low level of unsold assets or inventory.

Debt Coverage by Assets: 6OP's debt is covered by short term assets (assets are 7.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6OP has been profitable on average in the past, therefore cash runway is not a concern.

Forecast Cash Runway: 6OP has been profitable on average in the past, therefore cash runway is not a concern.


Next Steps

Dividend

What is OSE Immunotherapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6OP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 6OP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6OP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6OP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6OP's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Alexis Peyroles 0

1.8yrs

Tenure

€812,511

Compensation

Mr. Alexis Peyroles has served as Chief Executive Officer of OSE Immunotherapeutics SA since April 12, 2018 and serves as its Director. He served as Chief Operating Officer for Finance, Business Developmen ...


CEO Compensation Analysis

Compensation vs Market: Alexis's total compensation ($USD891.79K) is above average for companies of similar size in the German market ($USD419.45K).

Compensation vs Earnings: Alexis's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Dominique Costantini
Founder1.8yrs€304.28k13.01% 7.0m
Alexis Peyroles
Director & CEO1.8yrs€812.51kno data
Maryvonne Hiance
Vice Chairman & Director of Public Affairs3.8yrs€14.57k2.67% 1.4m
Anne-Laure Autret-Cornet
Chief Financial Officer3.8yrsno data0.089% 48.2k
Nicolas Poirier
Chief Scientific Officer & Director0.7yrsno data0.15% 82.1k
Alain Chatelin
Medical Director and Member of the Scientific Board0yrsno datano data
Bérangère Vasseur
Chief Medical Officer Immuno-Oncology2.1yrsno datano data
Julien Perrier
Chief Commercial Officer1.2yrsno datano data
Jean Conduzorgues
Director of Production & Member of the Scientific Board0yrsno datano data
Jean Theron
Consultant0yrsno datano data

1.8yrs

Average Tenure

Experienced Management: 6OP's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Dominique Costantini
Founder1.8yrs€304.28k13.01% 7.0m
Alexis Peyroles
Director & CEO1.8yrs€812.51kno data
Maryvonne Hiance
Vice Chairman & Director of Public Affairs3.8yrs€14.57k2.67% 1.4m
Nicolas Poirier
Chief Scientific Officer & Director0.7yrsno data0.15% 82.1k
Alain Chatelin
Medical Director and Member of the Scientific Board0yrsno datano data
Jean Conduzorgues
Director of Production & Member of the Scientific Board0yrsno datano data
Walter Flamenbaum
Independent Director5.7yrs€8.94kno data
Jean-Patrick Demonsang
Independent Director5.8yrs€21.43kno data
Gérard Tobelem
Independent Director5.8yrs€21.43kno data
Wolf-Hervé Fridman
Chairman of the Scientific Board6.3yrsno datano data

4.7yrs

Average Tenure

Experienced Board: 6OP's board of directors are considered experienced (4.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.


Top Shareholders

Company Information

OSE Immunotherapeutics SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OSE Immunotherapeutics SA
  • Ticker: 6OP
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €53.872m
  • Shares outstanding: 14.96m
  • Website: https://www.ose-immuno.com

Number of Employees


Location

  • OSE Immunotherapeutics SA
  • 22, boulevard Benoni Goullin
  • Nantes
  • Pays de la Loire
  • 44200
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OSEENXTPA (Euronext Paris)YesCommon StockFREURMar 2015
6OPDB (Deutsche Boerse AG)YesCommon StockDEEURMar 2015
0RADLSE (London Stock Exchange)YesCommon StockGBEURMar 2015
ORPO.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMar 2015
OSEPBATS-CHIXE (BATS 'Chi-X Europe')YesCommon StockGBEURMar 2015

Biography

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi, an immunotherapy that is in Phase III clinical stage for the treatment of lung cancer, as well as in Phase II clinical trial to pancreatic cancer; BI 765063, which is in Phase I clinical trial to treat solid tumors; and OSE-703, a humanized monoclonal antibody that is in preclinical stage for the treatment of various cancers. The company’s products also comprise FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-127, a humanized monoclonal antibody that is in Phase I clinical trial for the treatment of inflammatory autoimmune diseases. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, Servier, and HalioDx. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/28 22:03
End of Day Share Price2020/02/28 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.